Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Berman

Showing results (1241-1250 of 1,558) with videos related to

Pageof 156
Sort By:
Circulation. Cardiovascular Quality and Outcomes|July 29, 2010
Do major cardiovascular outcomes in patients with stable ischemic heart disease in the clinical outcomes utilizing revascularization and aggressive drug evaluation trial differ by healthcare system?Bernard R Chaitman, Pamela M Hartigan, David C Booth, et al.
Journal of the American College of Cardiology|July 2, 2011
Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trialDavid J Maron, William E Boden, John A Spertus, et al.
The Journal of Investigative Dermatology|November 10, 2021
Deep Learning and Pathomics Analyses Reveal Cell Nuclei as Important Features for Mutation Prediction of BRAF-Mutated MelanomasRandie H Kim, Sofia Nomikou, Nicolas Coudray, et al.
Circulation. Cardiovascular Imaging|September 20, 2022
Deep Learning for Explainable Estimation of Mortality Risk From Myocardial Positron Emission Tomography ImagesAnanya Singh, Jacek Kwiecinski, Robert J H Miller, et al.
Journal of Cardiovascular Computed Tomography|April 7, 2019
Validation of the Coronary Artery Calcium Data and Reporting System (CAC-DRS): Dual importance of CAC score and CAC distribution from the Coronary Artery Calcium (CAC) consortiumOmar Dzaye, Ramzi Dudum, Mohammadhassan Mirbolouk, et al.
Journal of the American College of Cardiology|October 15, 2021
Modeling the Recommended Age for Initiating Coronary Artery Calcium Testing Among At-Risk Young AdultsOmar Dzaye, Alexander C Razavi, Zeina A Dardari, et al.
The American Journal of Cardiology|July 7, 2009
Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial)William E Boden, Robert A O'Rourke, Koon K Teo, et al.
The American Journal of Cardiology|October 6, 2009
Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trialDavid J Maron, John A Spertus, G B John Mancini, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|September 24, 2016
Prognostic significance of blood pressure response during vasodilator stress Rb-82 positron emission tomography myocardial perfusion imagingBradley Witbrodt, Abhinav Goyal, Anita A Kelkar, et al.
Circulation. Cardiovascular Interventions|November 3, 2011
Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy: observations from the COURAGE TrialG B John Mancini, Pamela M Hartigan, Eric R Bates, et al.
Pageof 156

Showing results (1241-1250 of 1,558) with videos related to

Sort By:
Pageof 156
Circulation. Cardiovascular Quality and Outcomes|July 29, 2010
Do major cardiovascular outcomes in patients with stable ischemic heart disease in the clinical outcomes utilizing revascularization and aggressive drug evaluation trial differ by healthcare system?Bernard R Chaitman, Pamela M Hartigan, David C Booth, et al.
Journal of the American College of Cardiology|July 2, 2011
Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trialDavid J Maron, William E Boden, John A Spertus, et al.
The Journal of Investigative Dermatology|November 10, 2021
Deep Learning and Pathomics Analyses Reveal Cell Nuclei as Important Features for Mutation Prediction of BRAF-Mutated MelanomasRandie H Kim, Sofia Nomikou, Nicolas Coudray, et al.
Circulation. Cardiovascular Imaging|September 20, 2022
Deep Learning for Explainable Estimation of Mortality Risk From Myocardial Positron Emission Tomography ImagesAnanya Singh, Jacek Kwiecinski, Robert J H Miller, et al.
Journal of Cardiovascular Computed Tomography|April 7, 2019
Validation of the Coronary Artery Calcium Data and Reporting System (CAC-DRS): Dual importance of CAC score and CAC distribution from the Coronary Artery Calcium (CAC) consortiumOmar Dzaye, Ramzi Dudum, Mohammadhassan Mirbolouk, et al.
Journal of the American College of Cardiology|October 15, 2021
Modeling the Recommended Age for Initiating Coronary Artery Calcium Testing Among At-Risk Young AdultsOmar Dzaye, Alexander C Razavi, Zeina A Dardari, et al.
The American Journal of Cardiology|July 7, 2009
Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial)William E Boden, Robert A O'Rourke, Koon K Teo, et al.
The American Journal of Cardiology|October 6, 2009
Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trialDavid J Maron, John A Spertus, G B John Mancini, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|September 24, 2016
Prognostic significance of blood pressure response during vasodilator stress Rb-82 positron emission tomography myocardial perfusion imagingBradley Witbrodt, Abhinav Goyal, Anita A Kelkar, et al.
Circulation. Cardiovascular Interventions|November 3, 2011
Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy: observations from the COURAGE TrialG B John Mancini, Pamela M Hartigan, Eric R Bates, et al.
Pageof 156